Institutional Conflict of Interest and Equity Holdings

An institutional conflict of interest (ICOI) arises when the institution itself — not an individual investigator — has a financial interest that could bias the design, conduct, reporting, or oversight of research. The most common trigger is university equity in a faculty spinout company that is also sponsoring or conducting research on campus, but licensing royalties, industry gifts, and endowed positions tied to a sponsor all raise the same structural problem: the entity responsible for overseeing a study’s integrity has its own stake in a favorable outcome. This is a distinct compliance regime from individual investigator conflict of interest, with its own triggers, its own review body, and its own management logic.

Last verified 16 August 2026. This page draws on the Institute of Medicine’s 2009 consensus report Conflict of Interest in Medical Research, Education, and Practice (National Academies Press, available via NCBI Bookshelf) and on 42 CFR Part 50, Subpart F, the federal financial conflict of interest regulation for Public Health Service-funded research. Where institutional COI is a matter of institutional policy rather than a specific federal rule, that distinction is flagged explicitly below.

Institutional COI vs. individual investigator COI, side by side

Dimension	Individual investigator COI	Institutional COI
Whose interest is at stake	The researcher’s personal financial interest (equity, consulting income, royalties, board seats)	The institution’s own financial interest (equity, licensing revenue, gifts) — or a senior official’s personal interest exercised through institutional authority
Federal regulation	Explicitly mandated for PHS-funded research: 42 CFR Part 50, Subpart F requires disclosure above defined significant-financial-interest thresholds and a written, enforced institutional policy	No equivalent standalone federal rule requiring a specific institutional-COI regime for most funders; driven primarily by institutional policy, shaped by non-binding guidance (see below)
Who reviews it	The institutional COI office/committee, evaluating the individual against the institution’s written policy	A separate standing institutional-COI committee (often board-level, with independent/external members), structurally apart from the office and from technology transfer/investment management
Typical management tool	A management plan: disclosure, oversight by an independent co-investigator, removal from specific decisions, divestiture in some cases	A “rebuttable presumption” against the institution conducting or hosting the research at all while the financial interest exists, unless a compelling justification is documented
Common example	A faculty member holds equity in a company sponsoring their own study	The university itself holds equity in a spinout that is also sponsoring research on campus, or a department is funded by an endowed gift tied to that same sponsor

For the individual-investigator side of this table in full detail, see CASRAI’s NIH Financial Conflict of Interest guide and the broader Types of Conflict of Interest reference, which places “institutional” as one axis of a two-axis classification scheme.

What triggers an institutional conflict of interest

Per the IOM 2009 report, institutional COI arises from two structurally different sources, and institutions typically need separate procedures for each:

• The institution’s own financial interests — equity or other ownership stakes in a company sponsoring or benefiting from research conducted at the institution (most often a faculty spinout that has licensed university-owned IP); licensing or royalty revenue tied to a discovery currently under further study; gifts, grants, or endowed professorships funded by, or tied to, a company with a stake in a research outcome.
• A senior official’s personal financial interest exercised through institutional authority — a department chair, dean, provost, or technology transfer officer with a significant personal equity or consulting interest in a company, where that official also controls decisions affecting that company’s interests at the institution: hiring, lab space allocation, purchasing, or contract and licensing approval.

The university-equity-in-a-spinout scenario is the one most administrators mean when they say “institutional COI,” and it is the fastest-growing trigger as tech transfer activity increases: the more successful an institution’s licensing program, the more spinouts exist in which the institution itself holds stock, warrants, or a right to future royalties — and the more often that same spinout wants to sponsor or run a study on the campus that helped create it.

Checklist: does a situation need institutional-COI review, not just individual disclosure?

• Does the institution (not just an individual faculty member) hold equity, stock options, warrants, or a royalty/milestone interest in the company sponsoring, funding, or supplying the intervention for a study conducted at the institution?
• Is the study’s principal investigator, or any senior investigator on it, also a founder, officer, or significant equity holder of that same company? (If yes, this situation likely triggers both an individual FCOI review under 42 CFR Part 50 and a separate institutional-COI review — the two run in parallel, not instead of each other.)
• Does a department chair, dean, or other official with authority over the study’s resources (space, staffing, purchasing, contract sign-off) also hold a personal financial interest in the sponsor?
• Was the research funded, in whole or part, by a gift, endowed chair, or facility named for or tied to a company that also has a commercial interest in the study’s outcome?
• Does the technology transfer office’s own financial return (equity held in its portfolio, or an evergreen fund invested in the sponsor) create an institutional incentive around the outcome, separate from any individual’s interest?

Any “yes” is a signal to route the situation to the institutional-COI committee for review, not just the standard individual-disclosure workflow — see CASRAI’s Conflict of Interest Disclosure Form guide for the individual-level process this supplements rather than replaces.

How institutions structure institutional-COI oversight

The IOM 2009 report and subsequent institutional practice converge on a small set of structural controls, distinct from the tools used for individual FCOI:

• A separate standing committee. Rather than routing institutional financial interests through the same COI committee that reviews individual investigator disclosures, the report recommends a dedicated institutional-COI committee — often reporting to the board or a senior compliance officer — with members independent of the technology transfer office, the investment office, and the units whose research is under review.
• A rebuttable presumption against institutional involvement. Where the institution holds a direct financial stake in a study’s sponsor, the default position is that the institution should not conduct, host, or have its faculty lead that research — unless the institution can document a compelling reason to proceed and put additional safeguards in place. This reverses the usual disclosure-and-manage approach used for individual conflicts, which starts from the presumption that the research can proceed with a management plan.
• Separation of functions. The office that manages the institution’s equity, royalty, and investment portfolio (commonly the tech transfer or investment office) is kept organizationally separate from the office and committee that oversee research integrity and human-subjects protection for studies involving those same holdings, so the same office is never both financially interested in, and responsible for approving, the same study.
• Independent research oversight. For studies that do proceed despite an identified institutional interest, common safeguards include an external or otherwise independent data safety monitoring arrangement, an outside institution as the lead site or IRB of record, or independent monitoring of data integrity that does not run through the conflicted unit.
• Public reporting. Annual disclosure of identified institutional conflicts and how they were managed, consistent with the transparency expectation the IOM report and subsequent AAMC guidance both emphasize.

These structural recommendations are historically associated with cases where institutional and individual financial interests compounded each other with serious consequences — most prominently the 1999 gene-therapy trial death at the University of Pennsylvania, in which the lead investigator and the university both held financial interests connected to the study sponsor. That case is widely cited in the research-integrity literature as the reason institutional COI review became a distinct compliance function rather than an afterthought folded into individual disclosure.

Where this sits in the regulatory landscape

It matters administratively that institutional COI is not governed by the same kind of explicit, prescriptive federal rule as individual investigator FCOI. 42 CFR Part 50, Subpart F (the PHS/NIH financial conflict of interest regulation) sets disclosure thresholds, review timing, and management-plan requirements for investigators — it does not separately mandate a specific institutional-COI committee structure or a “rebuttable presumption” standard for the institution’s own holdings. Institutions build their institutional-COI policies voluntarily, most commonly drawing on the IOM 2009 report’s recommendations and on guidance the Association of American Medical Colleges (AAMC) has published on institutional financial interests in research, particularly for academic health centers and human-subjects research. In practice this means institutional-COI policy detail — what triggers review, how the standing committee is composed, what “compelling justification” means for rebutting the presumption — varies considerably across institutions in a way individual FCOI compliance, anchored to a single federal regulation, does not.

The university-equity-in-a-spinout case, worked through

The most common real scenario research administrators bring to an institutional-COI committee looks like this: a faculty member’s invention is licensed to a spinout under the institution’s standard tech-transfer terms, and the institution takes an equity stake as part of the license (a common, non-fabricated structural pattern — see CASRAI’s Funding Options for a University Spinout and Royalty vs. Equity comparison for how those stakes are typically structured). Two or three years later, that same spinout wants to sponsor a follow-on study at the institution — sometimes run by the same faculty founder, sometimes by a different investigator in the same department.

At that point, two separate reviews are typically triggered, not one:

1. Individual FCOI review (if the founder is involved as an investigator) under the institution’s standard 42 CFR Part 50-driven process — see CASRAI’s Faculty Conflict of Interest in Startups guide for how that individual-level disclosure and management plan works.
2. Institutional COI review, triggered independently by the institution’s own equity stake in the spinout, regardless of who the investigator is. This review asks a different question than the individual review: not “does this person’s involvement need a management plan,” but “should this institution be hosting or conducting this study at all, given its own financial stake in a favorable result.”

Because the two reviews ask different questions and often reach different committees, an institution can clear an individual investigator’s FCOI management plan and still have an open institutional-COI question — or vice versa. Research administrators handling a spinout-sponsored study should confirm both tracks have actually been checked, not assume that clearing one satisfies the other.

Frequently asked questions

Is institutional conflict of interest the same as an individual investigator’s financial conflict of interest?

No. Individual FCOI concerns a researcher’s personal financial interest and is explicitly regulated for PHS-funded research under 42 CFR Part 50, Subpart F. Institutional COI concerns the institution’s own financial interest — most often equity in a spinout — or a senior official’s personal interest exercised through institutional authority. The two require separate reviews and are not interchangeable, even though the same underlying company or technology can trigger both at once.

What is a “rebuttable presumption” in institutional-COI review?

It is the default position, recommended in the IOM 2009 report and used by many institutional-COI policies, that an institution should not conduct or host research in which it holds a direct financial stake in the sponsor — unless the institution documents a compelling justification for proceeding and puts additional independent safeguards in place. It shifts the starting assumption from “proceed with a management plan” (the usual approach to individual conflicts) to “don’t proceed unless justified.”

Does a university have to disclose its own equity holdings in a research sponsor?

Increasingly, yes, as a matter of institutional policy and public-reporting practice recommended by the IOM report and AAMC guidance — but this is not uniformly required by a single federal rule the way individual investigator disclosure is under 42 CFR Part 50. Practice varies by institution; check the specific institutional-COI policy in force rather than assuming a single national standard.

Who typically sits on an institutional-COI committee?

Common practice, per the IOM report’s recommendations, is a standing committee with members independent of the technology transfer office, the investment/endowment office, and the academic units whose research is under review — often reporting to the board or a senior compliance official rather than to the research office that also handles individual investigator disclosures.

Does clearing an individual investigator’s FCOI management plan also clear the institutional COI?

No. They are separate reviews answering separate questions. An institution can approve an individual’s management plan under its standard FCOI process while a distinct institutional-COI review, triggered by the institution’s own equity or royalty stake, is still open — administrators should confirm both tracks explicitly rather than assuming one covers the other.

Related CASRAI resources

• Conflict of Interest (COI) in Research — the underlying definition
• Types of Conflict of Interest — the actual/potential/perceived and financial/institutional classification axes
• NIH Financial Conflict of Interest — the individual investigator regime under 42 CFR Part 50
• NIH Conflict of Interest Policy
• Appearance of a Conflict of Interest
• Faculty Conflict of Interest in Startups — the individual faculty-founder case
• Funding Options for a University Spinout
• Royalty vs. Equity
• Conflict of Interest Disclosure Form
• Conflict of Interest Disclosure Statement Template